Sermorelin Employer + ICHRA Coverage: How to Manage Costs in 2026

Why Sermorelin Sits in a Coverage Gray Zone

Sermorelin acetate stimulates the pituitary to release endogenous growth hormone via growth-hormone-releasing hormone (GHRH) receptor agonism. The branded product Geref was withdrawn from the U.S. Market in 2008, leaving compounded sermorelin as the only available form. FDA-regulated 503A compounding pharmacies fill prescriptions on a patient-specific basis.

Because no FDA-approved sermorelin product currently exists, commercial and Medicare plans treat it as a non-covered compounded drug. That exclusion does not, however, prevent reimbursement through employer-funded arrangements governed by different rules.

What the FDA Says About Compounded Sermorelin

The FDA classifies compounded drugs under Section 503A of the Federal Food, Drug, and Cosmetic Act. A 503A pharmacy may legally prepare sermorelin for an individual patient when a licensed prescriber writes a valid, patient-specific prescription. The FDA has not placed sermorelin on the 503A Difficult-to-Compound or Withdrawn lists, meaning compounding remains permissible as of 2026.

Growth-hormone secretagogues like sermorelin act on the GHRH receptor (GHRHR). Pituitary responsiveness to GHRH declines with age, a process documented in studies of somatotropic axis physiology published in the Journal of Clinical Endocrinology and Metabolism. Veldhuis et al. (JCEM, 2006) measured a 14% per-decade decline in pulsatile GH secretion in healthy men, providing the physiological rationale for GHRH-based therapy.

Why Standard Insurance Won't Cover It

Group health plans governed by ERISA follow formulary rules tied to FDA approval status. A drug lacking an FDA-approved version cannot appear on a commercial formulary. Anthem, UnitedHealthcare, Aetna, and Cigna each publish explicit exclusions for compounded drugs that do not have an FDA-approved equivalent or that are listed as withdrawn. Patients who submit a claim through standard insurance for compounded sermorelin will receive a denial citing "not medically necessary" or "non-covered compounded product."

ICHRA and Sermorelin: The Most Direct Employer Coverage Path

An Individual Coverage Health Reimbursement Arrangement (ICHRA) lets an employer reimburse employees tax-free for qualifying medical expenses, including premiums and out-of-pocket costs. IRS Notice 2019-45 and the final ICHRA rule (84 FR 28888) established ICHRA as a permanent benefit option starting January 1, 2020.

What Qualifies as a Reimbursable Medical Expense

Reimbursable expenses must meet the IRC §213(d) standard: costs for the "diagnosis, cure, mitigation, treatment, or prevention of disease." IRS Publication 502 lists prescription medications as qualifying expenses. Compounded sermorelin prescribed for a documented diagnosis, such as adult growth-hormone deficiency (AGHD) or age-related hypopituitarism, meets this standard.

The documentation chain matters. A clean ICHRA reimbursement for sermorelin requires:

• A written diagnosis code (ICD-10 E23.0 for hypopituitarism or E34.8 for other specified endocrine disorders)
• A signed, patient-specific prescription from a licensed physician
• A pharmacy receipt showing the patient's name, drug name, and amount paid
• Submission through the employer's ICHRA plan administrator (e.g., Take Command Health, PeopleKeep, or Thatch)

How Much Employers Can Contribute

Congress set no upper limit on ICHRA employer contributions for 2026. Employers may define any annual reimbursement amount. Many small employers offering ICHRAs budget $200 to $600 per employee per month for total medical expenses. A sermorelin prescription averaging $200 per month could be fully absorbed within a modest ICHRA allowance without any employee out-of-pocket cost.

The HealthRX clinical team has outlined a four-step ICHRA reimbursement pathway specifically for compounded peptide prescriptions, based on the plan structures most commonly encountered by our patients in 2025 and 2026:

1. Confirm ICHRA eligibility with your HR department or benefits portal.
2. Obtain a diagnosis-coded prescription from your HealthRX-affiliated physician.
3. Fill at a compliant 503A pharmacy and request an itemized receipt.
4. Submit the receipt with your ICD-10 code attached to your ICHRA administrator within the plan's submission window (typically 60 to 90 days from the date of service).

What ICHRA Cannot Do

ICHRA funds cannot reimburse expenses that predate the employee's enrollment date. Retroactive claims are denied. Funds also cannot be used for drugs purchased from pharmacies outside the U.S., even if cheaper, because those purchases don't comply with FDA import rules. Using a foreign pharmacy voids the IRC §213(d) qualification and may expose the employee to IRS audit risk.

HSA and FSA Use for Sermorelin

Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) both allow pre-tax dollars to pay for qualifying medical expenses under IRC §213(d). Because sermorelin requires a prescription, it clears the basic prescription-drug test for HSA/FSA eligibility.

HSA Eligibility

To contribute to an HSA in 2026, an employee must be enrolled in a High-Deductible Health Plan (HDHP) with a minimum deductible of $1,650 (individual) or $3,300 (family), per IRS Rev. Proc. 2025-19. The 2026 HSA contribution limits are $4,300 (individual) and $8,550 (family), with a $1,000 catch-up for those 55 and older.

Paying for compounded sermorelin with HSA funds is legal when the prescription documents medical necessity. The HSA debit card or reimbursement check clears at the patient level; no plan-level approval is required. Keep the pharmacy receipt and the physician's prescription note in your records for at least three years in case of an IRS review.

FSA Eligibility and the "Use-It-or-Lose-It" Problem

FSA funds expire at year-end (with a possible $640 carryover or 2.5-month grace period in 2026, depending on the plan). Patients starting sermorelin late in the plan year should confirm they have sufficient FSA balance before filling a 90-day supply. A 90-day supply at $200 per month would cost $600, well within most FSA balances and a straightforward way to avoid year-end forfeitures.

The IRS explicitly addresses prescription drug expenses in Publication 502, confirming that prescribed medications qualify regardless of whether an FDA-approved equivalent exists, as long as the prescription is valid and the drug is legal to dispense in the U.S.

How to Get Sermorelin Cheaper: A Practical Cost Ladder

Cash prices for compounded sermorelin vary by dose, pharmacy, and vial size. The standard therapeutic dose ranges from 100 mcg to 300 mcg administered subcutaneously at bedtime, consistent with dosing studied in adults with GHRH deficiency. Walker et al. (JCEM, 1990) established pulsatile GH release at comparable GHRH analogue doses in the original pharmacokinetic work.

Pharmacy Selection

503A compounding pharmacies are not required to publish prices, so patients must call or use online telehealth platforms to compare. A 30-day supply of sermorelin 15 mg (reconstituted vial, 100 mcg per dose) ranges from $90 to $180 at PCAB-accredited compounding pharmacies. PCAB accreditation, offered through the Pharmacy Compounding Accreditation Board (a program of ACHC), signals compliance with USP Chapter 797 sterile-compounding standards. Choosing a PCAB-accredited pharmacy may also strengthen an ICHRA or HSA audit defense.

Telehealth Platforms and Bundled Pricing

Several telehealth hormone-optimization platforms, including HealthRX, negotiate volume pricing with compounding pharmacies and pass the savings to patients. Bundled programs that include physician consultation, lab work, and a 90-day medication supply may cost $350 to $600 total, which is often less than purchasing the components separately. Confirm that the telehealth platform's pharmacy is a licensed 503A facility in your state before providing payment information.

Manufacturer Coupons and Discount Cards

Discount cards like GoodRx do not typically index compounded drugs because compounded drugs lack a standard NDC (National Drug Code). RxSpark and NeedyMeds also apply primarily to FDA-approved branded or generic drugs. For compounded sermorelin, the most reliable discounts come from direct pharmacy pricing, telehealth bundles, and ICHRA or HSA reimbursement rather than third-party discount cards.

Dose Optimization to Reduce Cost

A prescriber may start a patient on 100 mcg nightly and increase only if follow-up IGF-1 levels remain low. Svensson et al. (JCEM, 1991) showed that GHRH-analogue doses above 1 mcg/kg/day did not produce proportionally greater GH release in adult men, suggesting that higher doses are not always necessary. Starting at the lowest effective dose and titrating based on lab results keeps monthly pharmacy costs down and avoids overpaying for unused therapeutic effect.

Documenting Medical Necessity: The Keystone of Any Coverage Claim

Whether the payment path is ICHRA reimbursement, HSA withdrawal, or FSA spending, documentation of medical necessity is the single element most likely to determine whether an audit succeeds or fails.

The AGHD Diagnosis Framework

Adult Growth Hormone Deficiency (AGHD) is defined by the Endocrine Society as a clinical syndrome confirmed by biochemical testing. The 2011 Endocrine Society Clinical Practice Guideline on AGHD states: "The diagnosis of GHD in adults requires biochemical confirmation using a validated GH stimulation test." The guideline recommends insulin tolerance testing (ITT) or glucagon stimulation testing as first-line, with a peak GH cutoff of <3 mcg/L for severe deficiency on ITT.

Patients who do not meet the strict AGHD biochemical threshold may still have a documented clinical indication, such as age-related somatotropic decline, sleep-onset disruption, or body-composition goals, that a physician can code under ICD-10 E34.8 or Z00.00 (routine adult health exam with abnormal findings noted). The coding choice affects how reviewers interpret the claim.

Lab Work That Supports the Case

A baseline IGF-1 level, drawn in the morning in a fasting state, provides objective evidence of somatotropic axis status. Reference ranges are age-stratified; for men aged 40 to 49, the LabCorp reference interval is 88 to 246 ng/mL. A result below the age-matched lower reference limit, even without a formal stimulation test, documents biochemical insufficiency and strengthens the medical-necessity argument for prescribing a GHRH secretagogue.

Ho et al. (NEJM, 1988) published the landmark study showing that GH-deficient adults had significantly increased fat mass and reduced lean body mass compared with controls, providing foundational evidence for treating GH axis dysfunction beyond pediatric height considerations. That paper (N=24 GH-deficient adults) is among the most-cited in adult GH research and is appropriate to reference in a medical-necessity letter.

Employer Benefits Navigation: A Step-by-Step Checklist

Many employees do not know their ICHRA balance, submission deadline, or whether their plan administrator has approved compounded drugs. The steps below apply broadly across 2026 plan years.

Step 1: Confirm Your Benefit Type

Ask HR: "Do I have an ICHRA, a QSEHRA, or a traditional group health plan?" A Qualified Small Employer HRA (QSEHRA) operates under similar IRC §213(d) rules but caps employer contributions at $6,350 (individual) or $12,800 (family) for 2026 per IRS Rev. Proc. 2025-28. ICHRA has no cap. Both can reimburse compounded sermorelin with proper documentation.

Step 2: Request a Summary Plan Description

The Summary Plan Description (SPD) must be provided free of charge under ERISA Section 104(b). Look for language about compounded drugs, prescription drug coverage, or excluded expenses. Most ICHRA SPDs do not list specific drugs as excluded; they rely on IRC §213(d) as the governing standard.

Step 3: Get the Right Prescription Format

Ask your prescribing physician to include:

• Your full legal name and date of birth
• The drug name (sermorelin acetate), concentration, and quantity
• The diagnosis or ICD-10 code
• The prescriber's DEA number and NPI
• A brief statement of medical indication (one to two sentences)

Many ICHRA administrators auto-approve prescriptions that include the ICD-10 code directly on the pharmacy receipt or the physician's letter.

Step 4: Submit With Evidence

Attach the itemized pharmacy receipt (showing patient name, drug, dose, and price paid), the prescription or physician letter, and your ICHRA claim form. Submit through your administrator's portal within the allowed window. Keep digital copies for three years.

Safety, Monitoring, and the Regulatory Compliance Layer

Using any reimbursement mechanism for sermorelin does not change the clinical obligation to monitor for adverse effects. Sermorelin is generally well-tolerated at therapeutic doses, with the most common side effects being injection-site reactions, water retention, and transient flushing. Prakash and Goa (BioDrugs, 1999) reviewed the clinical pharmacology of sermorelin and noted that local injection reactions occurred in approximately 17% of patients in early trials.

IGF-1 levels should be checked at baseline and at 3 months after starting therapy. A target IGF-1 in the upper-normal range for age (not above the normal ceiling) is the standard monitoring goal, consistent with Endocrine Society guidance. Supraphysiologic IGF-1 raises theoretical concerns about cell proliferation. Any patient whose IGF-1 rises above the age-matched upper reference limit should have the dose reduced or the drug held until the next clinic visit.

The FDA does not regulate the practice of medicine, but it does regulate compounding pharmacies. Patients should confirm their pharmacy's 503A registration on the FDA's database of registered human drug compounders before filling a prescription.